Biotech Values

[poorgradstudent]

>It's the language within the PR, moreso than the headline itself, that I think may be more revealing. The fact that they do not refer to the control arm along with the OGX-011 arm when noting the need for more survival updates to calculate median survival is what leads me to think maybe all events have in fact occurred in the control arm.<

Biotech rule of thumb: If it's a piece of information that bodes well for the trial, then 90% of small biotechs will make sure it is stated clearly and advantageously in the PR.

Conversely, if there are ambiguities, they are there because the specifics themselves may add a negative hue to the results.